UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

The New England journal of medicine, 2003-02, Vol.348 (9), p.800-807

2003

Volltextzugriff (PDF)

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Antimicrobial Agents and Chemotherapy, 2006-07, Vol.50 (7), p.2471-2477

2006

Volltextzugriff (PDF)

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

Antiviral therapy, 2007-01, Vol.12 (3), p.355-362

2007

Volltextzugriff (PDF)

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Journal of hepatology, 2003-12, Vol.39 (6), p.1085-1089

2003

Volltextzugriff (PDF)

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Journal of Virology, 2003-11, Vol.77 (21), p.11833-11841

2003

Volltextzugriff (PDF)

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

Hepatology (Baltimore, Md.), 2003-07, Vol.38 (1), p.96-103

2003

Volltextzugriff (PDF)

Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro

Antimicrobial Agents and Chemotherapy, 2004-10, Vol.48 (10), p.3702-3710

2004

Volltextzugriff (PDF)

Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3617-3632

2008

Volltextzugriff (PDF)

Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

Antimicrobial Agents and Chemotherapy, 2005-07, Vol.49 (7), p.2720-2728

2005

Volltextzugriff (PDF)

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy

Gastroenterology (New York, N.Y. 1943), 2004-06, Vol.126 (7), p.1750-1758

2004

Volltextzugriff (PDF)

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Gastroenterology (New York, N.Y. 1943), 2003-08, Vol.125 (2), p.292-297

2003

Volltextzugriff (PDF)

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2005-06, Vol.352 (26), p.2673-2681

2005

Volltextzugriff (PDF)

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

The New England journal of medicine, 2003-02, Vol.348 (9), p.808-816

2003

Volltextzugriff (PDF)

Time to Revisit Capital Maintenance on Profits Distribution: Lesson from Carillion and Beyond

European business law review, 2020-04, Vol.31 (Issue 2), p.265-284

Xiong, Xuedan (Shelly)

2020

Volltextzugriff (PDF)

New Series of Potent, Orally Bioavailable, Non-Peptidic Cyclic Sulfones as HIV-1 Protease Inhibitors

Journal of medicinal chemistry, 1996-08, Vol.39 (18), p.3431-3434

1996

Volltextzugriff (PDF)

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

Gastroenterology (New York, N.Y. 1943), 2003-07, Vol.125 (1), p.107-116

2003

Volltextzugriff (PDF)

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine- resistant HBV

Antiviral therapy, 2005-01, Vol.10 (5), p.625-633

2005

Volltextzugriff (PDF)

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438

Gastroenterology (New York, N.Y. 1943), 2003-07, Vol.125 (1), p.107-116

2003

Volltextzugriff (PDF)

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Hepatology (Baltimore, Md.), 2002-08, Vol.36 (2), p.464-473

2002

Volltextzugriff (PDF)

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

Journal of hepatology, 2006-01, Vol.44 (1), p.62-67

2006

Volltextzugriff (PDF)

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients

Journal of viral hepatitis, 2005-01, Vol.12 (1), p.67-73

2005

Volltextzugriff (PDF)

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

Antiviral research, 2004, Vol.61 (1), p.27-36

2004

Volltextzugriff (PDF)

Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro

Journal of hepatology, 2002-04, Vol.36, p.89-89

2002

Volltextzugriff (PDF)

Combinations of adefovir with lamivudine, entecavir, or L-dT produce additive antiviral effects against HBV in vitro

Journal of hepatology, 2002-04, Vol.36, p.23-23

2002

Volltextzugriff (PDF)

Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance

Gastroenterology (New York, N.Y. 1943), 2003-04, Vol.124 (4), p.A715-A715

2003

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro

Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

Time to Revisit Capital Maintenance on Profits Distribution: Lesson from Carillion and Beyond

New Series of Potent, Orally Bioavailable, Non-Peptidic Cyclic Sulfones as HIV-1 Protease Inhibitors

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine- resistant HBV

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro

Combinations of adefovir with lamivudine, entecavir, or L-dT produce additive antiviral effects against HBV in vitro

Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance

Suchergebnisse filtern